Rakovina Therapeutics (TSXV:RKV) Total Payout Ratio : 0.00 (As of Jul. 17, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Rakovina Therapeutics's current Total Payout Ratio is 0.00.

Rakovina Therapeutics Total Payout Ratio Historical Data

The historical data trend for Rakovina Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Total Payout Ratio Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

0.78

1.21

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Payout Ratio	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Rakovina Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, Rakovina Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Rakovina Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Rakovina Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	4.92	+	0)	/	-4.073
	=	1.21

Rakovina Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-2.18
	=	0.00

Rakovina Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

RKVTF:USA

Address

105 1008 Beach Avenue, Vancouver, BC, CAN, V6E 1T7

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before. The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Executives

Jeffrey Bacha	Senior Officer
Alfredo De Lucrezia	Director, Senior Officer
Michael Liggett	Director
Mads Daugaard	Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines